Abstract:Abstract Background The most well-known cause of cancer deaths identified in female is breast cancer. Several drugs approved by the food and drug administration (FDA) for the treatment of breast cancer may have adverse health effects. This research is aimed at developing a QSAR model and utilize it to predict the inhibitive activities of newly designed novel compounds, examine their ADMET and drug-likeness properties and carry out molecular docking studies between the designed compounds and the VEGFR-2 receptors in order to identify the essential amino acid residues involved in protein–ligand interactions and possible mechanism of action of the designed compounds. Results The first model was selected as the best because of its fitness statistically with the following assessment parameters: R 2 train = 0.832, R 2 adj = 0.79, R 2 ext = 0.62, Q 2 = 0.68, and LOF = 0.14509. Compound 11 was selected as a template to design new powerful compounds based on its low residual and high pIC 50 values. Majority of the designed compounds has predicted pIC 50 greater than that of the lead compound and the standard drug (Sunitinib) used as reference. Molecular docking studies results of the designed compounds revealed that they have higher docking scores than the template and the reference drug (Sunitinib) and are found to bind to the VEGFR-2 receptor in a similar manner to the reference drug. Pharmacokinetics and ADMET properties revealed that the designed compounds passed drug-likeness criteria because they did not violate more than 1 Lipinski’s rule of Five, They are uniformly distributed to the brain and are assumed to penetrate the central nervous system and finally they are all found to non-toxic and orally bioavailable. Conclusion The developed model was therefore found to be efficient in predicting the pIC 50 of Anti breast cancer compounds that are yet to be synthesized and it also help in reducing the cost and synthetic duration the compounds. The result of this research confirmed that the designed compounds may be developed as novel VEGFR-2 inhibitors.

Statistical Evaluation of Cancer Drugs by QSPR Modeling

Topological Indices and QSPR Modeling of New Antiviral Drugs for Cancer Treatment

Quantitative Structure–activity Relationship: Promising Advances in Drug Discovery Platforms

Utilizing topological indices in QSPR modeling to identify non-cancer medications with potential anti-cancer properties: a promising strategy for drug repurposing

QSAR Research of Novel Tetrandrine Derivatives Against Human Hepatocellular Carcinoma.

Estimating Physico-chemical Properties of Drugs for Prostate Cancer using Degree-Based and Neighbourhood Degree-Based Topological Descriptors

Topological coindices and QSPR analysis for some potential drugs used in lung cancer treatment via CoM and CoNM-polynomials

Quantitative structure-activity relationship and ADME prediction studies on series of spirooxindoles derivatives for anti-cancer activity against colon cancer cell line HCT-116

Implementation of multi-criteria decision making for the ranking of drugs used to treat bone-cancer

Quantitative Structure–Property Relationship Analysis in Molecular Graphs of Some Anticancer Drugs with Temperature Indices Approach

Quantitative Structure-Property Relationship (QSPR) Modeling of Drug-Loaded Polymeric Micelles Via Genetic Function Approximation

QSAR modeling for cytotoxicity of sulfur-containing Shikonin oxime derivatives targeting HCT-15, MGC-803, BEL-7402, and MCF-7 cell lines

Validating ADME QSAR Models Using Marketed Drugs

Reverse Degree-Based Topological Indices and QSPR Analysis of Cancer Drugs

Vertex-Edge Weighted Molecular Graphs: A study on topological indices and their relevance to physicochemical properties of drugs in use cancer treatment

QSPR Analysis of Drugs for Treatment of Schizophrenia Using Topological Indices

The study of curve fitting models to analyze some degree-based topological indices of certain anti-cancer treatment

Chemo-informatics activity prediction, ligand based drug design, Molecular docking and pharmacokinetics studies of some series of 4, 6-diaryl-2-pyrimidinamine derivatives as anti-cancer agents

Quantitative structure-electrochemistry relationship modeling of a series of anticancer agents using MLR and ANN approaches

Molecular modelling of antiproliferative inhibitors based on SMILES descriptors using Monte-Carlo method, docking, MD simulations and ADME/Tox studies

Exploring spectrum-based descriptors in pharmacological traits through quantitative structure property (QSPR) analysis